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Abstract
Estrogen receptor (ER)-B is the predominant ER sub-
type in prostate cancer (PCa). We previously demon-
strated that ICI 182,780 (ICI), but not estrogens, exerted
dose-dependent growth inhibition on DU145 PCa cells
by an ER-B–mediated pathway. Transcriptional pro-
filing detected a greater than three-fold upregulation of
seven genes after a 12-hour exposure to 1 MM ICI. Semi-
quantitative reverse transcriptase polymerase chain re-
action confirmed the upregulation of four genes by ICI:
interleukin-12A chain, interleukin-8, embryonic growth/
differentiation factor, and RYK tyrosine kinase. Treat-
ment with an ER-B antisense oligonucleotide reduced
cellular ER-B mRNA and induced loss of expression of
these genes. Sequence analysis revealed the presence
of consensus NFKB sites, but not estrogen-responsive
elements, in promoters of all four genes.Reporter assay
and chromatin immunoprecipitation experiments dem-
onstrated that ICI-induced gene expression could be
mediated by crosstalk between ER-B and the NFKB
signaling pathway, denoting a novel mechanism of ER-
B–mediated ICI action. Therefore, combined therapies
targeting ER-B and NFKB signaling may be synergistic
as treatment for PCa.
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Introduction
In the United States, prostate cancer (PCa) is the second
leading cause of cancer deaths in men. Approximately 50%
of men with PCa have locally advanced or metastatic
disease [1], and 30% of patients with apparent localized dis-
ease have biochemical relapse after the first line of treat-
ment [2]. Androgen ablation therapy is the mainstay
treatment for metastatic PCa [3], although most neoplasms
ultimately become androgen-refractory, at which time virtu-
ally no effective therapies are available. Therefore, there is a
strong demand for alternatives to the treatment of androgen-
insensitive PCa.
The pioneering work of Huggins and Hodges [4,5] estab-
lished the use of diethylstilbestrol (DES) as a low-cost and
effective treatment of metastatic PCa. However, because of
serious adverse side effects associated with DES treatment,
including exacerbation of heart failure, vascular complications,
and gynecomastia [6], this therapy has gone out of fashion
during the past two decades. Recently, interest in using estro-
genic therapies for advanced PCa has reemerged, primarily in
response to the following developments [7]. First, lower doses
of DES [DES in conjunction with antiandrogen therapies, an
estrogenic herbal therapy (PC-SPES), and 2-methoxy-estradiol
therapy] have proven effective in subpopulations of patients
with advanced PCa in phase 2 trials [8–10]. Second, admin-
istration of estrogens parenterally, which avoids hepatic first-
passmetabolism, appears to lower the risk of thromboembolism
[9]. Last, a second estrogen receptor (ER), the b subtype, has
been cloned [11] and shown to be expressed at high levels in
normal and malignant prostate epithelial cells [11–17], offering
a new molecular target for devising novel therapies.
We now know that the biologic effects of estrogens/anti-
estrogens are mediated by two ER subtypes ER-a and ER-b,
which are ligand-dependent transcription factors belonging to
the steroid/thyroid nuclear receptor superfamily [18]. Although
the DNA-binding domains of ER-a and ER-b share a high level
(86%) of amino acid homology, their N-termini, C-termini, and
ligand-binding domains (LBDs) have 23%, 17%, and 58% ho-
mology, respectively. Because of the divergence in their LBDs,
the two ER subtypes bind ligands (agonists or antagonists)
with different affinities [19,20]. After the ligands have bound to
these receptors, the complexes interact with specific DNA
sequences, known as estrogen response elements (EREs), on
the promoter regions of target genes, recruit coregulators and
components of the transcriptional machinery to the transcrip-
tional start site, and initiate transcription. Recent studies have
shown, however, that ERs may transactivate target genes by
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interacting with other transcriptional factors (TFs) such as
AP-1, instead of binding directly to EREs [21,22]. The utiliza-
tion of other TF-binding sequences is specific for both ligand
and receptor subtype [22]. This latter scenario adds com-
plexity to the mode of action of estrogens and/or antiestro-
gens and has presented new challenges in our attempts to
fully understand their action.
Using a highly specific ER-b antibody, we recently dem-
onstrated that ER-b is the predominant ER subtype ex-
pressed in normal basal epithelial cells of the prostate, in
local PCa, and in PCa metastasized to the lymph nodes and
bones [14]. We also showed that ER-b is expressed in
abundance in most established PCa cell lines, including
DU145, which we found to express only the b subtype of
ER [23,24]. Collectively, these data suggest that ER-b may
confer survival advantages to PCa cells [7]. Thus, targeted
activation or blockade of ER-b action with selective ligands
may present an attractive strategy for the therapeutic inter-
vention of PCa.
Our previous study [23] reported the inhibition of DU145
cell growth by the antiestrogen ICI 182,780 (ICI), but not 17-b
estradiol (E2), by an ER-b–dependent mechanism. Our
primary goal for this study was to discover putative ER-b–
regulated genes using transcriptional profiling to identify ICI-
regulated genes in DU145 cells. The proximal promoters of
four confirmed gene candidates all harbor NFnB cis-acting
elements, but not EREs. We further demonstrated the teth-
ering of ER-b with NFnB components. Collectively, these
data suggested that ER-b–NFnB crosstalk could be a new
mechanism of ER-b signaling with ligand or tissue specificity.
Materials and Methods
Cell Culture
The human PCa cell line DU145 and the human embry-
onic kidney cell line HEK293 were obtained from the Ameri-
can Type Culture Collection (ATCC; Manassas, VA). Cells
were routinely maintained in ATCC-recommended conditions.
Plasmids
The pSp13 luciferase reporter construct was kindly pro-
vided by Dr. Stephen Safe (Texas A&M University, College
Station, TX); the pNFnB luciferase reporter construct was
kindly provided by Dr. Francis Chan (University of Massa-
chusetts Medical School, Worcester, MA); the luciferase re-
porter plasmid (pt109-ERE3-Luc) carrying 3 vitellogenin
ERE was kindly provided by Dr. Criag Jordan (Fox Chase
Cancer Center, Philadelphia, PA); the ER-b expression plas-
mid was provided by Dr. Leigh C. Murphy (University of
Manitoba, Winnipeg, Canada); and the ERbD8 expression
vector was prepared by removing exon 8 of full-length ER-b
transcript, which we found to have no intrinsic transactivation
activity (unpublished data).
Chemicals and Reagents
The steroid E2 was purchased from Sigma (St. Louis, MO),
and ICI was a generous gift from Zeneca Pharmaceuticals
(Macclesfield, UK). E2 and ICI were dissolved in absolute
ethanol (Pharmco, Brookfield, CT). LipofectAMINE PLUS re-
agentwas purchased from Invitrogen (Carlsbad,CA),whereas
the luciferase assay and b-galactosidase enzyme assay sys-
tems were purchased from Promega (Madison, WI).
cDNA Microarray Analysis
The Atlas Human cDNAExpression Array (Clontech, Palo
Alto, CA), which includes 588 known genes, was used as
previously described [25]. Briefly, cells maintained in culture
medium containing 5% charcoal-stripped heat-inactivated
fetal bovine serum (FBS) were treated for 12 hours in the
absence or presence of 1 mM ICI. Cellular RNA was ex-
tracted and treated with DNase I, whereas polyadenylated
RNAwas isolated with two rounds of affinity chromatography.
[a-32P]dCTPwas used for cDNA probe synthesis from polyA-
RNA samples obtained from untreated and ICI-treated cells.
Approximately 0.6  106 cpm of each probe was hybridized
overnight to the membrane microarray with continuous agi-
tation at 68jC. After washing, hybridization signals on the
screens were read by phosphorimager Storm 830 (General
Electric Healthcare, Piscataway, NJ). The signal intensities of
spots were quantified with Kodak Image Analysis Software
(Eastman Kodak, Rochester, NY) and normalized against
the intensities of control cDNA on the arrays. Hybridization
signals from two separate experiments were used to identify
ICI-induced changes in gene expression profile.
Treatment of DU145 Cells with ICI, E2, or ER- Antisense
Oligodeoxynucleotide (ODN)
DU145 cells were seeded in six-well plates at a density of
3  105 cells/well in a final volume of 2 ml of culture medium
with 5% charcoal-stripped FBS. The effective concentration
of ICI to trigger apoptosis was determined previously [23].
Twenty-four hours after seeding, triplicate wells of cells were
treated with ICI (1 or 10 mM), E2 (10 or 100 nM), or 2.5 mM
ER-b antisense ODN for 4 days. The sequence of ER-b
antisense ODN has been described previously [23].
Reverse Transcriptase Polymerase Chain Reaction
(RT-PCR)
Total RNA was isolated with TRI reagent (Sigma) accord-
ing to the manufacturer’s protocol. After isolation, 1 mg of total
RNA was reverse-transcribed for 65 minutes at 42jC in 60 ml
of reaction mixture, including 5 mM MgCl2, 1 GeneAmp
PCR buffer II (50 mMKCl, 10 mM Tris–HCl, pH 8.3), 1 mM of
deoxynucleoside triphosphate, 5 nmol of random hexamers,
60 U of ribonuclease inhibitor, and 150 U of MuLV reverse
transcriptase. All reagents were purchased from Perkin-
Elmer (Shelton, CT). RT reaction was terminated by heating
to 95jC for 5 minutes, and 1 ml of the resulting cDNA was
used in each PCR.
Relative expression levels of interleukin-12a chain (IL-12),
interleukin-8 (IL-8), embryonic growth/differentiation factor
(GDF-1), RYK tyrosine kinase (RYK ), BFL-1, ER-a, ER-b,
and GAPDH were determined by semiquantitative RT-PCR
[23]. The sequences of primers used in this study are listed
in Table 1. Hot-start PCR using AmpliTaq Gold DNA
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polymerase (Perkin-Elmer) was used in all amplification re-
actions. The PCR programs were 24 cycles for GAPDH;
34 cycles for ER-a and ER-b; and 30 cycles of 30 seconds at
95jC, 45 seconds at 60jC, and 45 seconds at 72jC for other
genes. PCR products were subjected to electrophoresis in 2%
agarose gel with ethidium bromide, and fluorographs under
ultraviolet irradiation were captured by a Kodak DC290
digital camera (Eastman Kodak). The signals of the PCR prod-
uct were quantified with Kodak 1D Image Analysis software
(Eastman Kodak). Levels of GAPDH cDNA served as loading
control. Relative levels of mRNA for the genes were calcu-
lated following normalization against the signal intensity for
GAPDH mRNA.
Transient Transfection and Luciferase Assay
DU145 or HEK293 cells (4  104 cells/well) were plated
in 24-well plates (Corning, Corning, NY) in a final volume of
0.5 ml of culture medium with 5% charcoal-stripped FBS.
Cells were seeded for 24 hours before transfection so that
they could reach 70% confluence on the day of transfection.
All experiments were performed in triplicate. After 24 hours,
cells were transfected with LipofectAMINE PLUS reagent
(Invitrogen). Cells were transfected with 0.2 mg of lucifer-
ase reporter plasmid. Human ER-b expression plasmid
(0.05 mg) was applied to HEK293 cells during transfection,
and ERbD8 expression vector was used in the same experi-
ments to serve as control. Transfection efficiency was nor-
malized by cotransfecting 0.02 mg of pSV-b-galactosidase
control vector (Promega) in each case. After 24 hours, the
medium was changed, and cells were treated with vehicle
(dimethyl sulfoxide), E2, ICI, or a combination of E2 and ICI
for 48 hours. Luciferase assays were performed with the
Luciferase Assay System (Promega). b-Galactosidase ac-
tivity was measured with the b-Galactosidase Enzyme Assay
System (Promega).
Chromatin Immunoprecipitation (ChIP) Assay
DU145 cells were cultured in charcoal-stripped medium
for 3 days before treatment with E2 or ICI at a final concen-
tration of 10 nM and 1 mM, respectively, for another 24 hours.
Cells were incubated in a cross-linking buffer (1% formal-
dehyde) at 37jC for 10 minutes. Cells were harvested,
washed once with ice-cold 1 phosphate-buffered saline,
and resuspended in 500 ml of lysis buffer [1% sodium dodecyl
sulfate (SDS), 5 mM EDTA, 50 mM Tris–HCl (pH 8.1), and
1 Calbiochem protease inhibitor cocktail]. Cells were incu-
bated on ice for 10 minutes and sonicated thrice for 10 sec-
onds. The resulting lysate was precleared by centrifugation
for 10 minutes at 4jC and incubated with 45 ml of protein G
agarose beads (Upstate Biotechnology, Charlottesville, VA),
2 mg of sheared salmon sperm DNA, and 40 ml of normal
rabbit serum (Santa Cruz Biotechnology, Santa Cruz, CA) for
1 hour. After a brief centrifugation, the supernatant was
incubated with 8 mg of either p65- or ERb-specific antibody
(Santa Cruz Biotechnology) for 16 hours at 4jC. Immune
complexes were mixed with 40 ml of a protein G agarose sus-
pension followed by incubation for 1 hour at 4jC with rota-
tion. Bead pellets were sequentially washed for 10 minutes
with 1 ml each of the following buffers: low-salt wash buffer
[0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–Cl
(pH 8.1), and 150 mM NaCl], high-salt wash buffer [0.1%
SDS, 1% Triton X-100, 2 mMEDTA, 20 mM Tris–Cl (pH 8.1),
and 500 mM NaCl], and LiCl wash buffer [0.25 mM LiCl, 1%
Nonidet P-40, 1% sodium deoxycholate, 1 mM EDTA, and
10 mM Tris–Cl (pH 8.1)]. The beads were then washed
thrice with 1 ml of TE buffer [Tris–HCl (pH 8.0) and 1 mM
Table 1. Primer Sequence for RT-PCR Analysis.
Target Gene Primer Sequence Location (nt) Expected Size (bp)
RYK
RYK-F 5V-ATTTCCTGCACTTCACCTGG-3V 414–433 633
RYK-R 5V-CTTTGGCCTCCAAAAGAGTG-3V 1046–1065
GDF-1
GDF-1-F 5V-CTCATCGTCTCCTCCTACGC-3V 637–656 491
GDF-1-R 5V-GTTCAGAAGCGCTTGTCCTT-3V 1127–1146
IL-12
IL-12-F 5V-ACTCCAGACCCAGGAATGT-3V 402–421 590
IL-12-R 5V-AGGGACCTCGCTTTTTAGGA-3V 991–1010
IL-8
IL-8-F 5V-GTCTGTCAGCCAGGATCCAC-3V 845–864 499
IL-8-R 5V-ACACAGCTGGCAATGACAAG-3V 1343–1362
BFL-1
BFL-1-F 5V-TCTCAGCACATTGCCTCAAC-3V 116–135 482
BFL-1-R 5V-TACAAAGCCATTTTCCCAGC-3V 599–618
ER-b
ER-b-F 5V-TGAAAAGGAAGGTTAGTGGGAACC-3V 230–253 528
ER-b-R 5V-TGGTCAGGGACATCATCATGG-3V 737–757
ER-a
ER-a-F 5V-TACTGCATCAGATCCAAGGG-3V 41–60 650
ER-a-R 5V-ATCAATGGTGCACTGGTTGG-3V 671–690
GAPDH
GAPDH-F 5V-CCACCCATGGCAAATTCCATGGCA-3V 152–175 598
GAPDH-R 5V-TCTAGACGGCAGGTCAGGTCCACC-3V 726–749
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EDTA (pH 8.0)]. The immune complexes were eluted with
100 ml of freshly prepared elution buffer (1% SDS and 100mM
NaHCO3). Cross-linking reaction was reversed by overnight
incubation of DNA at 65jC, and samples were recovered
by DNA purification spin columns (Promega). Approximately
5% of the bound DNA fraction was used for PCR to detect
the proximal promoter region of the IL-8 locus, which has
been reported to contain a functional NFnB element [26].
As a control experiment, we have used a pair of primers to
amplify a DNA sequence containing an AP-2 site.
Statistical Analysis
Data are expressed as the mean of three experiments,
each with triplicate samples for individual treatments or
dosage regimens. Statistical analysis was carried out with
two-tailed Student’s t tests. Values are presented as mean ±
95% confidence intervals. All statistical tests were two-sided
and considered statistically significant at P < .02. One-way
ANOVA with Tukey B post hoc analysis was applied to de-
termine significance among different treatment groups in
DU145 transfection experiments.
Results
Investigation of Differential Gene Expression through
cDNA Microarray Analysis
To identify novel molecular targets of ICI in DU145 cells,
the Atlas Human cDNAExpression Array (Clontech) was used
for transcriptional profiling. The DU145 cells were used for
these experiments because this cell line exclusively expresses
ER-b [24]. Two independent transcriptional profiling experi-
ments were performed to identify ICI-induced changes in
DU145 cells. A three-fold increase in intensity was arbitrarily
used as a significant increase in gene expression (data not
shown). Seven genes (IL-12, IL-8,RYK,GDF-1,BFL-1, IGF-1,
and HTR-1A) were upregulated by antiestrogen treatment
in both array experiments. Among them, four genes (IL-12,
IL-8, GDF-1, and RYK ) were confirmed by semiquantitative
RT-PCR to show upregulation in ICI-treated DU145 cells
(Figure 1). The expression of other genes, which are observed
to be upregulated in the arrays, was found unaltered by ICI
treatment in confirmation experiments.
Upregulation of Gene Expression by ICI, But Not E2
Four genes were confirmed to be upregulated following
the treatment of DU145 cell cultures with ICI (Figure 1). A
three-fold increase in RYK and 2.0- to 2.5-fold increases in
GDF-1, IL-8, and IL-12 expression were detected when the
DU145 cells were treated with 1 or 10 mM ICI. It appears that
treatment with 1 mM ICI achieved almost the maximal level of
stimulation. In contrast, BFL-1 and ER-b gene expression did
not change significantly under the same experimental con-
ditions (Figure 1). Similarly, IGF-1 and HTR-1A expression
remained unchanged following ICI treatment (unpublished
data). Parallel experiments using 10 and 100 nM E2 as treat-
ment regimens did not induce expression changes in ICI-
regulated genes (unpublished data).
Effect of ER- Antisense ODN on Gene Expression
in DU145 Cells
To determine whether upregulation of target gene expres-
sion was mediated by an ER-b pathway, we used an ER-b
antisense ODN [23] to reduce ER-b mRNA levels in DU145
cells (Figure 2). A 60% reduction in the ER-b mRNA level
was achieved following transfection of PCa cells with 2.5 mM
ER-b antisense ODN. Concomitantly, the transfection re-
duced the expression of RYK, GDF-1, IL-12, and IL-8, but
Figure 1. Confirmation of ICI-induced gene expression in a dose-dependent study. DU145 cells (3  105 cells/well) were plated in triplicate on a six-well plate. After
24 hours of cell attachment, the cells were treated for 4 days with two concentrations of ICI: 1 M (grey bars) and 10 M (black bars). Cells treated with vehicle
(white bars) were used as controls. Three individual experiments were performed. Data are presented as mean (columns) and standard deviation (bars); Student’s
t test was applied to compare gene expression levels of ICI-treated cells (1 or 10 M) versus their respective controls. **P < .02 compared with control.
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not BFL-1 (Figure 2). Reduction in the levels of RYK,GDF-1,
IL-12, and IL-8 mRNA in the transfected cells ranged from
30% to 80%. These results indicated that downregulation of
ER-b expression in DU145 cells was associated with re-
duced expression of newly identified ICI-regulated genes.
Analysis of Cis-Acting Elements in the Gene
Promoter Region
To further elucidate the mechanisms underlying the reg-
ulation of gene expression in prostate by ICI, we used
MatInspector (www.genomatix.de) to identify common cis-
acting elements in the proximal promoter regions of these
ICI-regulated genes (Table 2). Interestingly, all of the genes
have the NFnB-binding element, whereas the Sp1 site was
found in three of four genes. However, only one of the gene
promoters contained an ERE. These results suggested that
transcriptional activities of ICI-regulated genes were related
to these cis-acting elements.
Transcriptional Activation of ER-b by ICI or E2
by an NFnB/Sp1–Binding Sequence
To provide experimental evidence that the transcrip-
tional activation of ER-b by ICI or E2 is mediated by an NFnB-
B- or an Sp1-binding element, we transiently transfected
DU145 cells, which we demonstrated to express only the b
subtype of ER [23,24], with a luciferase reporter gene driven
by a promoter carrying either a tandem NFnB- or an Sp1-
binding sequence. Relative luciferase activity data showed
that transactivation at the NFnB element was about 10 times
more robust than that at the Sp1 element in untreated DU145
cells (background activities). We then evaluated the li-
gand dependency of transactivation by these two cis-acting
elements by treating the cells with ICI and/or E2 (Figure 3A).
ICI was found to be more potent than E2 in the transactiva-
tion of the reporter gene. Cotreatment of DU145 cells with ICI
and E2 markedly reduced reporter activity to a level lower
than that induced by ICI, suggesting that the two ligands
competed for the same endogenous ER-b pool.
To demonstrate that ICI preferentially used NFnB/Sp1
over the classic ERE, we then conducted transfection experi-
ments in HEK293 cells, which have no detectable expression
of ER (-a and -b, data not shown). HEK293 was transiently
transfected with expression vectors carrying wild-type ER-b
or an inactive mutant (ERbD8). In the absence of ligand, no
transactivation activities were detected with all combinations
of receptors and cis-regulatory elements. As expected, at the
classic ERE, E2 exerted agonistic action, whereas ICI was
antagonistic. In contrast, at the NFnB element, both E2 and
ICI were potent inducers of luciferase expression, with a
three-fold induction. Similarly, two ligands both served as
agonists at the Sp1 site, inducing an approximately 2.5-fold
increase in reporter activity. These data confirmed the find-
ing that ER-b could tether on Sp1 for transactivation [27], but
revealed for the first time that ER-b also crosstalked with
the NFnB signaling. To definitely demonstrate direct inter-
action between ER-b and the subunit of the NFnB complex
in DU145 cells, we performed a ChIP assay with a well-
characterized promoter (IL-8) that contains a single NFnB-
binding element in a specific promoter region [26]. Our data
clearly demonstrated that ER-b was recruited to an NFnB-
binding site on the IL-8 promoter possibly by interaction
with p65. To demonstrate sequence specificity, we have
conducted control experiments using primers to amplify an
Figure 2. Downregulation of ER- expression is associated with reduction in the expression of putative ICI-regulated genes. DU145 cells (3  105 cells/well) were
plated in triplicate on a six-well plate. Cells were treated with ER- antisense ODN (black bar). After 4 days of treatment, total RNA was extracted and subjected to
RT-PCR analyses. Three individual experiments were performed. Student’s t test was applied to compare gene expression in antisense ODN-treated cells versus
their untreated controls. Data are presented as mean (columns) and standard deviation (bars). **P < .02 compared with control.
Table 2. Promoter Region Analyses in ICI-Regulated Genes.
NFnB Sp1 AHRARNT ERE AP-1 E2F
IL-8 + +
IL-12 + + + +
RYK + + + + +
GDF-1 + + + +
246 ICI-regulated Genes in Prostate Cancer Cells Leung et al.
Neoplasia . Vol. 8, No. 4, 2006
unrelated DNA sequence (AP-2 site), and we found no
amplification products (Figure 3C).
Discussion
We have successfully used transcriptional profiling to identify
ICI-regulated genes in the DU145 PCa cell line. Among the
genes identified by array analysis, four genes (IL-12, IL-8,
GDF-1, and RYK ) were confirmed by semiquantitative RT-
PCR to be upregulated by ICI, but not E2. Reduction of cellular
ER-b mRNA levels achieved with antisense ODN transfec-
tion in DU145 cells resulted in downregulation of these
genes, suggesting that ER-b plays an essential role in their
maintenance. In silico analysis revealed the presence of a
consensus NFnB cis-acting element, but not ERE, in the pro-
moters of all four genes and of an Sp1 site in the promoters
of three genes. In DU145 cells that expressed only ER-b, ICI,
but not E2, acted as a potent agonist in activating reporter
expression by the NFnB, whereas both ligands could trans-
activate gene transcription by an Sp1-responsive element. In
contrast, in an ER-null cell line (HEK293) expressing trans-
genic ER-b, E2 and ICI both acted as agonists at both NFnB
and Sp1 sites but served as an agonist and an antagonist,
respectively, at the classic ERE. ChIP analysis using chroma-
tin isolated from DU145 cells revealed a direct interaction
between the ER-b and a short region of the IL-8 promoter
containing an NFnB-binding site. Collectively, these data sug-
gested that ER-b may use multiple and diverse mechanisms
in gene regulation.
Estrogens and antiestrogens, including several selective
estrogen receptor modulators (SERMs), have been implicated
as potential therapeutic agents for androgen-independent
Figure 3. (A) Effects of E2 and ICI on the induction of Sp1- and NFjB-driven reporter activities in DU145 cells. Cells were transiently transfected with pSp13 or
pNFjB luciferase reporter plasmid. After 24 hours of transfection, cells were treated with vehicle only (untreated), 10 nM estradiol (E2), 10 M ICI (ICI), or 10 nM E2
+ 10 M ICI (E2 + ICI). After 48 hours, cells were harvested and assayed for luciferase activity. Luciferase values were corrected for transfection efficiency by
measuring the -galactosidase activity of cotransfected pSV--galactosidase construct. Three individual experiments were performed. Data are presented as
mean (columns) and standard deviation (bars). One-way ANOVA with Tukey B post hoc analysis was applied to determine significance among different treatment
groups in this experiment. *P < .01 compared with untreated Sp1 control; #P < .01 compared with untreated NFjB control. (B) Comparison of ER- transactivation
efficiency on various DNA-binding elements on E2 and ICI treatment in ER- –overexpressed HEK293 cells. Transfection experiments were performed as
described in Materials and Methods section. After 24 hours of transfection, cells were treated with vehicle (dimethyl sulfoxide), 10 nM E2, or 1 M ICI. ER- and
ERD8 are the expression vectors expressing wild-type ER- and inactive mutant, respectively, whereas ERE, NFjB, and Sp1 are the reporter vectors used in
this study. Three individual experiments were performed. Data are expressed as mean (columns) and standard deviation (bars). (C) ChIP analysis of ER- and p65
on IL-8 promoter. DU145 cells were treated with either 10 nM E2 (left panel) or 1 M ICI (right panel). ChIP assay was performed as described in Materials and
Methods section. After reverse cross-linking and DNA purification, PCR was performed to confirm the involvement of the NFjB element on the IL-8 promoter. As a
control for sequence specificity, PCR was performed using primers for a sequence containing an AP-2 element. No signal was detected in any of the
immunoprecipitated pulldown products, except for the total DNA input.
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PCa [7]. However, their mechanisms of action in the genesis
and progression of PCa are still unclear. It seems controver-
sial that both estrogen agonists and antagonists can induce
the inhibition of cell growth or apoptosis in androgen-
independent human PCa cell lines [28–30]. This observation
is due, in part, to the complexity of the interactions between
ER and the coactivators/corepressors within the promoter
regions of target genes [14]. The discovery of the ER-b sub-
type in human prostates [31] opened up a new chapter in the
understanding of estrogen signaling pathways and provided
important clues into the role of estrogen/ER in prostate
carcinogenesis. In this study, we chose DU145 cells, which
expressed only the ER-b subtype, to study the mechanism
of cell growth inhibition by the pure antiestrogen ICI [11].
The induction of G0–G1 cell cycle arrest by ICI was mediated
by the ER-b subtype because this biologic effect could be
reversed by exposure of the cells to an ER-b antisense ODN.
Recently, another SERM, raloxifene, which is a mixed estro-
gen agonist/antagonist, has been shown to induce apoptosis
in DU145 cells, mostly likely mediated by ER-b [29]. In con-
trast, the antiprostatic and antitumor responses in the PAIII
rat PCa cells elicited by trioxifene (LY133314) are mediated
by ER-a, but not by ER-b, and are considered to be an SERM
with selective ER-a antagonist activity in prostate malig-
nancy [30]. The different responses of ER-a and ER-b to dif-
ferent SERMs may be attributed to structural dissimilarities
in their N-terminal A/B and LBDs, as well as to their interac-
tions with different coregulators in target tissues. In addition,
homodimerization or heterodimerization among ER sub-
types also plays a significant role in the determination of
ligand-binding affinity [32].
Gene regulation mediated by ER uses classic and non-
classic pathways [33]. In a classic pathway, ligand-bound ER
directly binds to a palindromic ERE to turn on gene transcrip-
tion. Ligands such as E2 are classified as estrogens if they
are agonistic at the ERE, and as antiestrogens (ICI or tamoxi-
fen) if they exert antagonistic action at the same site. How-
ever, in noncanonic pathways, ER initiates transcription by
interacting with third-party proteins, such as Jun/Fos, that
transactivate at an AP-1 site [34] or with an Sp1 protein bind-
ing to an Sp1 element [35]. Using this mechanism, anti-
estrogens may behave like agonists [22]. In the presence of
E2 or classic estrogens, ER-a tends to use the classic path-
way. In contrast, when ER-b binds to SERMs or antiestrogens
such as ICI, it prefers to activate target genes by molecular
tethering to AP-1 [34] or Sp1 sites [27,36]. We observed here
that both ICI and E2 were agonistic at an Sp1 site through
interaction with endogenous ER-bs in DU145 cells or with
transgenic ER-bs in HEK293 cells. These findings suggested
that, in DU145 cells, ER-b activated by ICI employs non-
classic pathways for signaling. Recognizing the small number
of probes in our cDNA array, it is logical to predict that if high-
density arrays were to be used in future experiments, many
ICI-regulated molecular targets could be identified. It will be
interesting to determine which subsets of these targets would
use these nonclassic ER-b signaling pathways.
Another molecular tether for ER-b in DU145 cells that we
found was NFnB. Although NFnB has been reported to in-
teract with ER-a to mediate gene transcription [37], before
our study, no direct evidence has demonstrated its inter-
action with this ER subtype. In DU145 cells, only ICI, but not
E2, caused significant enhancement of reporter activity. Un-
expectedly, in HEK293 cells expressing transgenic ER-b, we
found that both E2 and ICI can transactivate the reporter
through the NFnB element. Taken together, these data sug-
gested that ligand-dependent activation of ER-b on the NFnB
cis-acting element is dependent on cell context, which may
include the absence/presence of different nuclear receptor
coactivators, as well as posttranslational activation of the
receptor. Additionally, ChIP assays using chromatin ex-
tracted from DU145 cells treated with either E2 or ICI showed
direct interactions between ER-b and p65 targeting at the
NFnB site, yet only ICI caused significant transactivation
in this cancer cell line. One explanation for this discrepancy
is that only ICI-liganded ER-b could recruit a functional set
of coregulators to trigger transactivation, whereas the
E2-liganded ER-b could not. Further investigations are need-
ed to dissect the complexity of TF crosstalk in various cell
types, such as those exemplified in our model.
NFnB-regulated genes are often shown to be antiapop-
totic and to enhance survival in specific cell types [38].
Inhibition of NFnB by salicylate has been shown to sensitize
the cells to programmed cell death by proapoptotic drugs [39].
We previously reported that 4 days of treatment of DU145
cells with ICI induced the inhibition of cell growth [23], which
we now discovered to be caused by apoptosis (unpublished
data). In this study, we identified several early-response (12
hours) genes that are upregulated by an ICI-induced ER-b/
NFnB tethering mechanism. This finding appears to be
paradoxical to the general belief that NFnB-regulated genes
protect against apoptosis. A possible explanation is that
upregulation of the NFnB gene family is the first line of cellular
response when DU145 cells are challenged with ICI. With
prolonged treatment, other ICI-stimulated ER-b signaling
pathways are turned on and finally trigger apoptosis. The
involvement of ER-b in ICI-induced apoptosis is further
supported by the inability of ICI to initiate programmed cell
death in ER-b–null glioma cells [39]. This finding raises the
possibility that modulation of NFnB signaling may signifi-
cantly alter the apoptotic sensitivity of PCa cell toward ICI-
induced ER-b–mediated cell death.
In summary, we have identified several ICI-induced early
response genes in DU145 cells whose expression may be
regulated by a novel mechanism involving ER-b tethering on
an NFnB complex. Because both primary and metastatic PCa
express primarily the ER-b subtype, therapies targeting both
TFsmay give rise to novel modalities for the treatment of PCa.
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